Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers H > Headlines for HedgePath Pharmaceuticals, Inc. > News item |
HedgePath Pharmaceuticals plans to price public sale of common stock
Agent H.C. Wainwright assists; deal finances research and development
By Devika Patel
Knoxville, Tenn., Sept. 17 – HedgePath Pharmaceuticals, Inc. will price a public offering of its common stock, according to a Form S-1 filed Wednesday with the Securities and Exchange Commission.
H.C. Wainwright & Co., LLC is the agent for the deal, which is being conducted on a best-efforts basis.
Proceeds will be used for research, development, working capital and general corporate purposes.
The biopharmaceutical company is based in Tampa, Fla.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.